TY - JOUR
T1 - Structural basis of the atypical activation mechanism of KRASV14I
AU - Bera, Asim K.
AU - Lu, Jia
AU - Wales, Thomas E.
AU - Gondi, Sudershan
AU - Gurbani, Deepak
AU - Nelson, Andrew
AU - Engen, John R.
AU - Westover, Kenneth D.
N1 - Funding Information:
Acknowledgments—Results shown in this report are derived from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source. Argonne is operated by the University of Chicago Argonne, LLC, for the United States Department of Energy, Office of Biological and Environmental Research under contract DE-AC02-06CH11357.
Funding Information:
This work was supported by National Institutes of Health Grant U54 CA196519, a V Foundation for Cancer Research V Scholar Grant, DOD Grant W81XWH-16-1-0106 (to K. D. W.), and a research collaboration grant with the Waters Corporation (to J. R. E.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2019 Bera et al.
PY - 2019/9/20
Y1 - 2019/9/20
N2 - RAS regulation and signaling are largely accomplished by direct protein-protein interactions, making RAS protein dynamics a critical determinant of RAS function. Here, we report a crystal structure of GDP-bound KRASV14I, a mutated KRAS variant associated with the developmental RASopathy disorder Noonan syndrome (NS), at 1.5-1.6 Å resolution. The structure is notable for revealing a marked extension of switch 1 away from the G-domain and nucleotide-binding site of the KRAS protein. We found that this extension is associated with a loss of the magnesium ion and a tilt in the position of the guanine base because of the additional carbon introduced by the isoleucine substitution. Hydrogen-deuterium exchange MS analysis confirmed that this conformation occurs in solution, but also disclosed a difference in kinetics when compared with KRASA146T, another RAS mutant that displays a nearly identical conformation in previously reported crystal structures. This conformational change contributed to a high rate of guanine nucleotide-exchange factor (GEF)-dependent and -independent nucleotide exchange and to an increase in affinity for SOS Ras/Rac GEF 1 (SOS1), which appears to be the major mode of activation for this RAS variant. These results highlight a mechanistic connection between KRASA146T and KRASV14I that may have implications for the regulation of these variants and for the development of therapeutic strategies to manage KRAS variantassociated disorders.
AB - RAS regulation and signaling are largely accomplished by direct protein-protein interactions, making RAS protein dynamics a critical determinant of RAS function. Here, we report a crystal structure of GDP-bound KRASV14I, a mutated KRAS variant associated with the developmental RASopathy disorder Noonan syndrome (NS), at 1.5-1.6 Å resolution. The structure is notable for revealing a marked extension of switch 1 away from the G-domain and nucleotide-binding site of the KRAS protein. We found that this extension is associated with a loss of the magnesium ion and a tilt in the position of the guanine base because of the additional carbon introduced by the isoleucine substitution. Hydrogen-deuterium exchange MS analysis confirmed that this conformation occurs in solution, but also disclosed a difference in kinetics when compared with KRASA146T, another RAS mutant that displays a nearly identical conformation in previously reported crystal structures. This conformational change contributed to a high rate of guanine nucleotide-exchange factor (GEF)-dependent and -independent nucleotide exchange and to an increase in affinity for SOS Ras/Rac GEF 1 (SOS1), which appears to be the major mode of activation for this RAS variant. These results highlight a mechanistic connection between KRASA146T and KRASV14I that may have implications for the regulation of these variants and for the development of therapeutic strategies to manage KRAS variantassociated disorders.
UR - http://www.scopus.com/inward/record.url?scp=85072514302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072514302&partnerID=8YFLogxK
U2 - 10.1074/jbc.RA119.009131
DO - 10.1074/jbc.RA119.009131
M3 - Article
C2 - 31341022
AN - SCOPUS:85072514302
SN - 0021-9258
VL - 294
SP - 13964
EP - 13972
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 38
ER -